Tolerability, Pharmacokinetics and Efficacy of ZSP1603 in Patients With Idiopathic Pulmonary Fibrosis （IPF）

NCT05119972 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

15

Enrollment

INDUSTRY

Sponsor class

Conditions

Idiopathic Pulmonary Fibrosis (IPF)

Interventions

DRUG: ZSP1603
DRUG: Placebo

Sponsor

Guangdong Raynovent Biotech Co., Ltd